peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Biopharma: Issue and repurchase of class C shares for incentive programs

9 Dec 2021, 17:31
Regulatory information

Lund December 9, 2021. The board of directors of Hansa Biopharma AB (publ) (“Hansa”), (Nasdaq Stockholm: HNSA) today resolved to issue 440,452 new class C shares and to immediately thereafter repurchase such 440,452 issued class C shares. Today’s resolution by the board of directors was passed based on the authorisation granted by the annual general meeting held on 12 May 2021.

Svenska Handelsbanken AB (publ) will subscribe for all issued class C shares at a subscription price of SEK one (1) per share. All 440,452 issued class C shares will be repurchased by Hansa at a purchase price of SEK one (1) per share. Following the share issue, the share capital will increase by SEK 440,452. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.

The purpose of the share issue and the repurchase is to enable potential future delivery of ordinary shares in accordance with long term incentive programs based on employee stock options adopted by the annual general meeting held on 23 June 2020 and the annual general meeting held on 12 May 2021 as well as to cover any social charges associated with the mentioned, or other outstanding, programs. The class C shares will be converted to ordinary shares before any delivery to the participants in the programs.

Hansa currently holds 1,421,457 class C shares and will, following the repurchase of the newly issued 440,457 class C shares, hold all 1,861,909 class C shares in the company.

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326

About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at